Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report
2024

Resistance Patterns in HIV-2 Infection: A Case Report

Sample size: 1 publication 10 minutes Evidence: moderate

Author Information

Author(s): van Kampen Jeroen J A, van Nood Els, Mahmud Rizwan, Krullaars Zoë, Voskamp Tess, Voskamp Mike, Nijssen Tess, Voermans Jolanda J C, Charpentier Charlotte, Le Hingrat Quentin, van de Vijver David, Gruters Rob, Mesplède Thibault

Primary Institution: Erasmus MC, Rotterdam, The Netherlands

Hypothesis

What are the resistance patterns of HIV-2 to dolutegravir and lenacapavir?

Conclusion

Lenacapavir shows potential in treating HIV-2 but must be combined with other effective antiretroviral agents to prevent resistance.

Supporting Evidence

  • Lenacapavir was added to a failing regimen, initially reducing viral load.
  • Resistance mutations were identified during treatment.
  • The patient experienced a rebound in viral load despite initial improvements.

Takeaway

This study looks at a patient with HIV-2 who had trouble getting better with certain medicines, but found some new options that helped a little.

Methodology

The case of a treatment-experienced individual was reported, including clinical monitoring and resistance assays.

Potential Biases

Potential conflicts of interest were reported for some authors.

Limitations

The study is based on a single case, limiting generalizability.

Participant Demographics

An adult female diagnosed with HIV-2 in 2002.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/ofid/ofae705

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication